Infant Ibuprofen Recall Hits Walmart, CVS, Family Dollar Stores

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Infant Ibuprofen Recall Hits Walmart, CVS, Family Dollar Stores

© kieferpix / iStock

New Jersey-based drugmaker Tris Pharma has voluntarily recalled three lots of its ibuprofen product for babies following the company’s discovery that some packages contained higher amounts of ibuprofen than may be safe. The medicine is sold at Walmart Inc. (NYSE: WMT), CVS Health Corp. (NYSE: CVS) and Family Dollar stores, according to the company’s announcement.

At Walmart, the product is sold under the “Equate” brand. CVS sells the medicine under its “CVS Health” brand, and Family Dollar sells it under the “Family Wellness” brand. The recalled product is further identified as “ibuprofen concentrated oral suspension, USP (NSAID) 50 mg per 1.25 mL, 0.5 oz. bottle.” NSAID refers generally to non-steroidal anti-inflammatory drugs.

Tris said there is a “remote possibility” that some infants who may be susceptible to higher doses of ibuprofen “may be more vulnerable to permanent NSAID-associated renal injury.” The company noted that to date it has received no reports of adverse effects related to the recalled products.

[nativounit]

Tris said it sold the affected lots to one customer that then distributed the product into the U.S. market. The drugmaker has notified the distributor by “urgent recall notice” and is also arranging for the return of the recalled product.

At Walmart, the affected lot numbers are 00717009A with an expiration date of 02/19, 00717015A expiring 04/19 and 00717024A expiring 08/19. The affected lot number at CVS and Family Dollar stores is 00717024A expiring 08/19.

Adverse effects that may be experienced by infants who have been given the medicine are nausea, vomiting, epigastric pain, or more rarely, diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible adverse effects.

[recirclink id=509447]

[wallst_email_signup]

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618